(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 30 September 2004 (30.09.2004)

(10) International Publication Number WO 2004/083363 A3

(51) International Patent Classification7: A61K 39/395. A61P 25/00 // C07K 16:28

(21) International Application Number:

PCT/EP2004/001016

(22) International Filing Date: 2 February 2004 (02.02.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0306309.6

19 March 2003 (19.03.2003)

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): VINSON, Mary [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). IRVING, Elaine, Alison [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).
- (74) Agent: LEAROYD, Stephanie, Anne; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 2 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTICAL USE OF ANTI-MYELIN ASSOCIATED GLYCOPROTEIN (MAG) ANTIBODIES

(57) Abstract: A method of promoting oligodendrocyte survival in a human suffering or at risk of developing stroke or another neurological disease which comprises administering to said human a therapeutically effective amount of an anti-MAG antibody or a functional fragment thereof.

International Application No

		The second secon	T/EP2004/001016	
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K39/395 A61P25/00 //C07K16/28			
According to	o International Patent Classification (IPC) or to both national classifi	cation and IPC		
	SEARCHED			
IPC 7	ocumentation searched (classification system followed by classifical A61K	lion symbols)		
Documentat	tion searched other than minimum documentation to the extent that	such documents are included	In the fields searched	
	ata base consulted during the international search (name of data between all of the se	ase and, where practical, sear	ch terms used)	
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.	
X	WO 02/062383 A (VINSON MARY ;IRV ALISON (GB); SMITHKLINE BEECHAM 15 August 2002 (2002-08-15) claim 7	ING ELAINE PLC (GB)	1-19	
X	WO 95/22344 A (BRAUN PETER ERICH ;MCKERRACHER LISA JOAN (CA); UNI (CA); D) 24 August 1995 (1995-08 page 16, line 21 - page 18, line page 21, line 3 - line 14; claim	V MCGILL 1-24) 34	1-10	
X	WO 99/53945 A (BRAUN PETER ERICH ;MCKERRACHER LISA JOAN (CA); DAV (CA)) 28 October 1999 (1999-10-2 claims 1-23	ID SAMUEL	1-10	
		-/		
X Furti	her documents are listed in the continuation of box C.	χ Patent family memb	pers are listed in annex.	
A docume	ategories of cited documents: ent defining the general state of the art which is not defend to be of particular relevance	or priority date and not cited to understand the	d after the international filing date in conflict with the application but principle or theory underlying the	
"E" earlier of filing of "L" docume	document but published on or after the international date ent which may throw doubts on priority claim(s) or	invention X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"O' document referring to an oral disclosure, use, exhibition or other means document is combined with one or a ments, such combination being obv		o involve an inventive step when the		
	ent published prior to the international filing date but han the priority date claimed	in the art. *&* document member of the	e same patent family	
Date of the	actual completion of the international search	Date of mailing of the in	lemational search report	
1	3 September 2004	24/09/2004	I	
Name and r	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer		
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Le Flao, k	(


International Application No T/EP2004/001016

		T/EP2004/001016			
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	NIEDEROEST BARBARA ET AL: "Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1." JOURNAL OF NEUROSCIENCE, vol. 22, no. 23, 1 December 2002 (2002-12-01), pages 10368-10376, XP002296056 ISSN: 0270-6474 page 10369, right-hand column, last paragraph	1-19			
Α	WONG SCOTT T ET AL: "A p75NTR and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein." NATURE NEUROSCIENCE, vol. 5, no. 12, December 2002 (2002-12), pages 1302-1308, XP002296057 ISSN: 1097-6256 the whole document	1-19			
E	WO 2004/014953 A (GLAXO GROUP LTD; ELLIS JONATHAN HENRY (GB); GERMASCHEWSKI VOLKER (GB)) 19 February 2004 (2004-02-19) claims 1-26	1-10			
•					

nternational application No.

PCT/EP2004/001016

Вох	No. I	Nu	ucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With	regard	to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed e international search was carried out on the basis of:
	a.	type of	f material
		x	a sequence listing
			table(s) related to the sequence listing
	b.	format	of material
		х	in written format
		х	in computer readable form
	c.	time o	f filing/furnlshing
		X	contained in the international application as filed
			filed together with the international application in computer readable form
		X	furnished subsequently to this Authority for the purpose of search
2.	х	or fu	ddition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed urnished, the required statements that the information in the subsequent or additional copies is identical to that in the lication as filed or does not go beyond the application as filed, as appropriate, were furnished.
з.	Add	itional c	omments:
			·
			· ·



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1, 3-19 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
-
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
. No protest accompanied the payment of additional search fees.

information on patent family members

International Application No
I/EP2004/001016

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
WO 02062383	A	15-08-2002	EP WO JP US	1357941 02062383 2004523538 2004170627	A2 T	05-11-2003 15-08-2002 05-08-2004 02-09-2004
WO 9522344	Α	24-08-1995	AU CA WO	1703595 2183630 9522344	A1	04-09-1995 24-08-1995 24-08-1995
WO 9953945	Α	28-10-1999	AU WO	3134799 9953945	• -	08-11-1999 28-10-1999
WO 2004014953	Α	19-02-2004	WO	2004014953	A2	19-02-2004